Recent Updates
Recently added Catalysts

ABBV-112i

Phase 1

Undisclosed | Small Molecules | Other |AbbVie Inc.|Trials Updated: Nov 12, 2026

ABBV-112i target and mechanism

ModalitySmall Molecules

Also known as [11C]ABBV-112i

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment6

FDA Designations

No designations recorded

ABBV-112i clinical trials

ABBV-112i · 1 trial · 1 indication

Early Phase 1 1
NCT07933497M4 Receptor PET Radioligand Validation Study in Healthy AdultsHealthy Volunteers
NOT YET_RECRUITING6 Analytics
EARLY_PHASE1NOT YET_RECRUITING
M4 Receptor PET Radioligand Validation Study in Healthy Adults
Healthy Volunteers
NCT079334976
Unlock trial analytics

Study Endpoints

Primary Endpoints

Regional brain volume of distribution (VT) of ABBV-112i across brain regions
Up to Approximately Up to Day 1

VT defined as the ratio of radioligand concentration in the tissue region of interest to that observed in plasma at equilibrium.

Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
[11C]ABBV-112iEXPERIMENTALParticipants will receive two single intravenous bolus doses of \[11C\]ABBV-112i, with each dose followed by up to approximately 90 minutes dynamic PET scan.

Interventions

NameTypeDescription
[11C]ABBV-112iDRUGIntravenous Bolus
Unlock Study Design Details

Eligibility Criteria

Age Range23 Years to 55 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * BMI is \>= 18.5 to \<= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history, physical examination, v...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 12, 2026NCT07933497NEW_TRIAL: changed
LOWNov 12, 2026NCT07933497NEW_TRIAL: changed

Explore more on BiopharmaWatch

AbbVie Inc. (ABBV)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ACompanies A to ZEvery biotech and pharma company we track